Schonfeld Group Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Schonfeld Group Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$223K	Buy	+2,365	New	+$219K	0.14%	197

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Schonfeld Group Holdings's ALNY Position: Q4 2015 in Review

Schonfeld Group Holdings opened a new position in Alnylam Pharmaceuticals (ALNY) in Q4 2015: 2,365 shares worth $223K. The stake represents 0.14% of the portfolio and ranks #197 among its holdings.

260 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

Schonfeld Group Holdings held 2,365 shares of Alnylam Pharmaceuticals worth $223K as of Q4 2015.
Alnylam Pharmaceuticals was a new Schonfeld Group Holdings position in Q4 2015.
Alnylam Pharmaceuticals made up 0.14% of Schonfeld Group Holdings's portfolio in Q4 2015, its #197 holding.
260 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on Schonfeld Group Holdings's 13F filing for Q4 2015, filed 12 Feb 2016.